ATM and neoplasm: First, although caspase activation is believed to be a common feature of tumor cells treated with oncogene-matched targeted therapies, and although we demonstrate targeted therapy-induced ATM activation in diverse oncogene-driven models, the full breadth of scenarios in which ATM inhibition may be used to potentiate the activity of targeted therapies is yet to be determined.